Podcasts

Nataliya Uboha, MD, PhD, discusses the FDA approval of first-line tislelizumab-jsgr with platinum-containing chemotherapy for unresectable or metastatic ESCC.

Drs. Grivas and Park discuss developments in bladder cancer research, including the potential of HER2-targeted therapies and PD-1/PD-L1 inhibitors in the neoadjuvant setting.

Virginia Kaklamani, MD, DSc, discusses the mechanism of action of inavolisib and the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm.

Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.

Marwan G. Fakih, MD discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial, and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

Christopher L. Moertel, MD, discusses the significance of the FDA approval of mirdametinib, based on efficacy and safety data from the phase 2 ReNeu trial.

Dr Bardia discusses the significance of the FDA approval of Dato-DXd, and pivotal findings from the phase 3 TROPION-Breast01 trial that led to the approval.

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.

Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER+/HER2- metastatic breast cancer.

Hear Chandler Park, MD and Stephen Liu, MD, explore advancements in EGFR-mutated NSCLC treatment, including TKI strategies, emerging therapies prioritizing a patient-centric approach.

Dr Campos discusses clinical implications from the gynecologic cancer cohorts of DESTINY-PanTumor02 and considerations for managing adverse effects in patients receiving T-DXd.

Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma.

Kevin Kalinsky, MD, MS, discusses his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer evolving into the future.

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

Hear Alan P. Venook, MD, discuss recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal cancers.

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

Martin Dietrich, MD, PhD, discusses updated efficacy findings from the 18-month follow-up of the phase 2 VISION trial.

In case you missed any, read a recap of every episode of OncLive On Air that aired in September 2024.

Drs Park and Patil discuss the evolving small cell lung cancer treatment paradigm, focusing on PCI, immune checkpoint inhibitors, and recent study data.

Drs Thomas and Lukas discusses highlights in brain cancer research from the 2024 ASCO Annual Meeting.

In this episode, Drs Park and Patil discuss key updates from the 2024 ASCO Annual Meeting, including the significance of data from the phase 3 LAURA trial.

D. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.

Drs Armstrong and Tawagi discuss high-yield oncology and hematology topics to focus on when studying for the 2024 oncology board exams.

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.